Related Experiment Videos

Proliferation in pituitary adenomas: measurement by MAb KI 67

K Kitz1, E Knosp, W T Koos

  • 1Department of Neurosurgery, Vienna Medical School, Wien, Austria.

Acta Neurochirurgica. Supplementum
|January 1, 1991
PubMed

Insights

The monoclonal antibody KI 67 can identify proliferating pituitary tumor cells. Higher KI 67 labeling index correlates with invasive pituitary adenomas, aiding in diagnosis.

Area of Science:

  • Oncology
  • Immunohistochemistry
  • Endocrinology

Background:

  • Proliferating tumor cells are key indicators of tumor behavior.
  • The monoclonal antibody KI 67 (MAb KI 67) targets a nuclear antigen present throughout the cell cycle.
  • This antibody facilitates the evaluation of proliferating cells in various tissue preparations.

Purpose of the Study:

  • To investigate the utility of MAb KI 67 in assessing pituitary adenomas.
  • To determine the correlation between MAb KI 67 labeling index (LI) and tumor invasiveness.

Main Methods:

  • A total of 120 pituitary adenomas were analyzed using MAb KI 67.
  • A two-step avidin-biotin-peroxidase complex (ABC) technique was employed for immunohistochemical staining.
  • Histological examination of the sellar floor dura was performed in 90 surgically treated cases.

Main Results:

  • The KI 67 LI in the studied pituitary adenomas ranged from 0.2% to 4.6%.
  • Pituitary adenomas with confirmed dural infiltration exhibited a statistically significant higher KI 67 LI (p < 0.001).
  • This finding suggests a correlation between proliferation markers and tumor invasiveness.

Conclusions:

  • MAb KI 67 is a valuable tool for evaluating cell proliferation in pituitary adenomas.
  • A higher KI 67 LI is associated with increased invasiveness of pituitary adenomas.
  • Immunohistochemical assessment using MAb KI 67 can aid in predicting tumor behavior and guiding treatment strategies.

Related Concept Videos